Surrozen, Inc. Form 8-K Summary
Reporting event: April 1, 2024; filed April 2, 2024. The filing reports a material private placement and related registration rights arrangements. It does not provide quarterly or annual operating results, revenue, profit, cash flow, margins, debt, or liquidity balances.
Transaction and Key Financial Terms
- Surrozen entered into a Securities Purchase Agreement with institutional investors and management.
- The company agreed to issue investors 1,089,033 common shares and pre-funded warrants to purchase up to 40,000 common shares.
- Purchase prices were $15.50 per share and $15.4999 per pre-funded warrant, generating approximately $17.5 million of gross proceeds before placement-agent fees and other expenses.
- Management separately agreed to purchase 2,948 shares at $16.96 per share.
- Pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire until exercised in full.
Warrants and Potential Dilution
- Series A: Warrants for up to 1,129,033 shares at $15.50 per share, exercisable immediately for five years. Management also received Series A warrants for 2,948 shares at $16.96 per share.
- Series B: Warrants for up to 1,228,071 shares at $14.25 per share, exercisable until the fifth trading day after specified SZN-043 Phase 1b enrollment, mortality, safety-review, and dose-escalation milestones. Management also received Series B warrants for 3,206 shares at $15.71 per share.
- Series C: Warrants for up to 4,375,000 shares at $16.00 per share, exercisable for 30 days after announcement of final SZN-043 Phase 1b data or upon certain fundamental transactions. Management also received Series C warrants for 11,424 shares.
- Series D: Warrants for up to 4,375,000 shares at $16.00 per share, exercisable for 30 days after announcement of enrollment of at least 50 patients in the SZN-043 Phase 2/3 trial or upon certain fundamental transactions. Management also received Series D warrants for 11,424 shares.
- Exercise of the warrants could provide additional gross proceeds of approximately $17.5 million from Series A, approximately $17.5 million from Series B, and approximately $70 million each from Series C and Series D, excluding management warrants.
- The transaction creates substantial potential future dilution if the pre-funded warrants and common warrants are exercised. Certain warrants may be cancelled or become subject to mandatory transfer if milestone-related exercise conditions are not met.
Registration Rights and Securities Law Matters
- The securities were sold in an unregistered private placement under Section 4(a)(2) of the Securities Act and Regulation D.
- Surrozen agreed to file a resale registration statement within 15 days after closing and use reasonable best efforts to obtain effectiveness as promptly as practicable, and no later than 90 days after closing if the SEC conducts a full review.
- The shares and warrant securities may not be resold in the United States absent registration or an applicable exemption.
Outlook, Milestones, and Risks
- The warrant structure ties portions of potential financing and dilution to clinical milestones for SZN-043, including Phase 1b safety and enrollment outcomes in severe alcohol-associated hepatitis and later Phase 2/3 enrollment.
- The filing does not provide management guidance, a cash runway estimate, clinical efficacy results, or a stated use of proceeds.
- Risks include failure to achieve the specified clinical milestones, inability to access potential warrant exercise proceeds, future dilution, restrictions on resale, and possible cancellation or mandatory transfer of warrants under the warrant terms.
Important Facts for Investors to Verify
- Confirm the closing date and actual net proceeds after placement-agent fees and other expenses.
- Review the company’s capitalization table and the total number of shares outstanding after issuance and any pre-funded warrant exercises.
- Read the complete warrant terms for milestone definitions, termination dates, adjustment provisions, and fundamental-transaction rights.
- Verify the timing and effectiveness of the resale registration statement.
- Assess Surrozen’s available cash, operating cash burn, debt, and funding requirements in its latest periodic filing, as those financial figures are not included in this 8-K.